Erbagil in Space: Erbagil Research Beyond the Boundaries of Gravity
Erbagil's participation in a space mission represents a unique milestone in the history of Italian biotechnology research. The goal is to analyze the behavior of Ozoile® Food , Erbagil's patented bioactive complex, in microgravity conditions to understand how weightlessness affects the stability, bioavailability, and biological activity of functional substances.
The study, conducted in collaboration with scientific partners and space institutions, aims to explore new applications in nutraceuticals and preventive medicine, both on Earth and in future long-term space environments.
Microgravity and biotechnology: a new frontier for Ozoile®
Studying Ozoile® Food in microgravity means pushing the limits of traditional research, to more deeply understand how cells react to weightlessness and how bioactive properties can maintain their effectiveness even in extreme environments.
The experiment will allow us to observe biological processes that are difficult to replicate on Earth, paving the way for new applications in the nutraceutical and pharmaceutical fields.
In this context, Erbagil brings into space not just a molecule, but an integrated vision of health , where nutrition, biotechnology and the environment dialogue to build a more sustainable future.
A research that combines the concreteness of the earth with the pioneering power of space, testifying to the universal value of Italian scientific innovation.
Erbagil® and Its Space Revolution
Erbagil® has achieved a scientific milestone of international significance by participating in the prestigious NG-20 Cygnus mission, which culminated with the launch of the Falcon 9 rocket from the Kennedy Space Center . As part of the mission, the MiniLab 1.0 , intended for biological research, was transported into orbit aboard the Falcon 9 with the aim of testing molecules capable of mitigating cellular aging processes in microgravity conditions.
The entire mission was made possible thanks to the strong collaboration between Erbagil® and the Department of Biology at Federico II University, within a scientific agreement that combined academic expertise and industrial innovation capabilities. The research group led by Professor Geppino Falco, full professor at the aforementioned Department, conducted a series of studies on Ozoile® in its laboratories to evaluate its biological activities, including its effect on the viability and differentiation of mesenchymal stem cells in the molecular processes associated with osteoporosis.
Based on the results obtained, Ozoile® was deemed an important and innovative product worthy of inclusion in the READI SP project, conceived by Prof. Falco and supported by Erbagil® Ricerca, resulting in the launch of the MiniLab into space, reaching the International Space Station.
This experience represents not only international recognition for Erbagil®, but also a concrete example of how the synergy between research and business can generate cutting-edge, sustainable solutions projected towards the future of regenerative medicine – even beyond the confines of the Earth.
